Dear Collaborators @cyanover @JMPark @Vojtech_Huser,
Thank you very much for your help improving our protocol and for pointing out inconsistencies regarding the terms, “observation” and, “lookback.” Your insight has helped us improve the language and clarity of our work.
In my previous forum post, I had indicated that we would require a 24-month observation period; this was incorrect, as the 24-month lookback period prior to index date was meant to build a time window around the index date in which a diagnosis of AD could be made, NOT that we require a 24-month period of observation prior to the index date.
In revisiting our protocol, we have now disambiguated, “index date,” replacing it with DDD#1 -first date of dupilumab dispensing and ADD#1- first date of AD diagnosis.
We have also taken another look at Aim 3 (assessing time between first diagnosis of AD and the start date of dupilumab) and have chosen to include a longer lookback period (12 years, by consensus of University of Colorado team members).
Our updated protocol and cohort definition (JSON) are attached.
Thanks again, and we look forward to working with you!
AD_OHDSI_Protocol Version3.docx (112.1 KB)
AD OHDSI Cohort JSON Updated Lookback 6.28.21.docx (18.1 KB)